News

These days, finding dividend payers that offer eye-popping yields is as easy as clicking the sort button on your favorite stock screener. Unfortunately, the vast majority of stocks that float to the

Hardly for the first time this year, biotech CymaBay Therapeutics (NASDAQ: CBAY) had a winning day on the market Monday. Following the news that its leading drug candidate had been granted an

Shares of Revolution Medicines (NASDAQ: RVMD) were crashing 42.5% lower as of 11:13 a.m. ET on Monday. The steep decline came after the oncology company presented results on Sunday for RMC-6236 from

Cathie Woods, through her various ARK funds, has been scooping up shares of Intellia Therapeutics (NASDAQ: NTLA), Block (NYSE: SQ), and Ginkgo Bioworks (NYSE: DNA) lately. All three stocks have

AT&T (NYSE: T) may finally have begun a long-awaited rebound. The stock surged 7% higher following its earnings announcement for the third quarter of 2023. A possible reason for the increase may

Some stocks have the "it" factor. They've got such tremendous growth prospects that investors want to add them to their portfolios without any hesitation.

Three Motley Fool investors think they've

On October 13, Pfizer (NYSE: PFE) served up a platter of bad news for investors. Aside from lowering its estimates for sales of its jab and its antiviral pill for COVID, the company reported that

Like it or not, inflation remains higher than Americans have been accustomed to, and the impacts of last year's price surge have not gone away. As of September, inflation as measured by the Consumer

AT&T (NYSE: T) has a history dating back to the late 1800s. And over many periods of that long and storied history, it's been a fantastic stock to own.

However, over the last 10 years, AT&T stock

AT&T's (NYSE: T) stock rallied nearly 7% on Oct. 19 after the telecom giant posted its third-quarter earnings report. Its revenue rose 1% year over year to $30.35 billion and surpassed analysts'

Pfizer (NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock

Pfizer (NYSE: PFE) last year brought in record sales of more than $100 billion thanks to its dominance in the coronavirus prevention and treatment markets. The company sells the top vaccine

Shares of AT&T (NYSE: T) were gaining for the second day in a row today as a flurry of positive analyst notes gave the stock another boost. As of 1:37 p.m. ET, the stock was up 1.5% after gaining as

Shares of Knight-Swift Transportation (NYSE: KNX) were moving higher today after the diversified transportation company topped analyst estimates in its third-quarter earnings report.

As of 11:27

If you had to choose a stock for the investing hall of shame over the last decade, AT&T (NYSE: T) would be a good candidate.

It's made two of the worst acquisitions of this century, spending more

Telecom giant AT&T (NYSE: T) surprised investors on Thursday with third-quarter results that sent its stock flying. Not only did AT&T beat analyst expectations for both revenue and earnings per

Shares of Summit Materials (NYSE: SUM) were up 8% as of 11:30 a.m. ET on Thursday after the construction materials provider filed a preliminary statement with the Securities and Exchange Commission

Image source: The Motley Fool.

AT&T (NYSE: T)Q3 2023 Earnings CallOct 19, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived --

For a company in the midst of a transition away from the medicine that made it a star performer over the last decade, AbbVie's (NYSE: ABBV) valuation looks surprisingly high. Why is the market

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have been in agreement on a lot since the beginning of the pandemic. They both recognized the importance of eventually launching combined vaccines --

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q3 2023 Earnings CallOct 18, 2023, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press

Exelixis (NASDAQ: EXEL) is not exactly a household name in the biotech industry, but that hasn't stopped the company from crushing the market this year -- rising over 30%. Perhaps one key reason